FRA:ECX - Deutsche Boerse Ag - DE000A37FT41 - Common Stock - Currency: EUR
FRA:ECX (6/27/2024, 7:00:00 PM)
0.7
-0.09 (-11.17%)
The current stock price of ECX.DE is 0.7 EUR. In the past month the price decreased by -57.32%. In the past year, price increased by 52.84%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 21.07 | 346.68B | ||
1ABBV.MI | ABBVIE INC | 20.82 | 342.48B | ||
AMG.DE | AMGEN INC | 16.43 | 161.21B | ||
1AMGN.MI | AMGEN INC | 16.41 | 160.89B | ||
1GILD.MI | GILEAD SCIENCES INC | 25.67 | 135.84B | ||
GIS.DE | GILEAD SCIENCES INC | 25.39 | 134.40B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1667.04 | 115.58B | ||
ARGX.BR | ARGENX SE | 248.77 | 33.10B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 23.75B | ||
IDP.DE | BIOGEN INC | 9.25 | 20.54B | ||
1BIIB.MI | BIOGEN INC | 8.76 | 19.21B | ||
0QF.DE | MODERNA INC | N/A | 12.84B |
Epigenomics AG is a DE-based company operating in Biotechnology industry. The company is headquartered in Berlin, Berlin and currently employs 18 full-time employees. The company went IPO on 2004-07-19. Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. The company develops and commercializes blood-based diagnostic products across multiple cancer indications. The firm's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. The company also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The firm is present in Europe and the United States.
EPIGENOMICS AG
Geneststrasse 5
Berlin BERLIN DE
Employees: 18
Company Website: https://www.epigenomics.com/
Phone: 4930243450
The current stock price of ECX.DE is 0.7 EUR. The price decreased by -11.17% in the last trading session.
The exchange symbol of EPIGENOMICS AG is ECX and it is listed on the Deutsche Boerse Ag exchange.
ECX.DE stock is listed on the Deutsche Boerse Ag exchange.
6 analysts have analysed ECX.DE and the average price target is 16.32 EUR. This implies a price increase of 2231.43% is expected in the next year compared to the current price of 0.7. Check the EPIGENOMICS AG stock analysts ratings, price target forecast and up-and down grades for more detailed information.
EPIGENOMICS AG (ECX.DE) has a market capitalization of 23.90K EUR. This makes ECX.DE a Nano Cap stock.
EPIGENOMICS AG (ECX.DE) currently has 18 employees.
EPIGENOMICS AG (ECX.DE) has a resistance level at 1.72. Check the full technical report for a detailed analysis of ECX.DE support and resistance levels.
The Revenue of EPIGENOMICS AG (ECX.DE) is expected to grow by 2136.83% in the next year. Check the estimates tab for more information on the ECX.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ECX.DE does not pay a dividend.
EPIGENOMICS AG (ECX.DE) will report earnings on 2024-09-30.
EPIGENOMICS AG (ECX.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-17.68).
ChartMill assigns a fundamental rating of 2 / 10 to ECX.DE. ECX.DE has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months ECX.DE reported a non-GAAP Earnings per Share(EPS) of -17.68. The EPS decreased by -7359.64% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -386.29% | ||
ROE | -853.33% | ||
Debt/Equity | 0.06 |
ChartMill assigns a Buy % Consensus number of 80% to ECX.DE. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 47.75% and a revenue growth 2136.83% for ECX.DE